Wright launches biologic grafting system:
This article was originally published in Clinica
Wright Medical, of Arlington, Tennessee, has released a new, minimally-invasive biologic grafting system onto the US market. The product is intended for use in core decompression surgical procedures. Core decompression is used to treat patients with early stage avascular necrosis (AVN) of the hip. The biologic grafting system combines the new X-Ream expandable reamer with Wright's proprietary Pro-Dense injectable graft. To use the system, the surgeon first drills a small channel through the "neck" of the femur, to access and "decompress" the diseased bone. The X-Ream device is then inserted into the channel, and the tip expanded and rotated, removing the necrotic bone. The Pro-Dense graft is then injected into the space, in order to regenerate healthy bone. Further launches in other countries are slated for early 2008.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.